Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations
Ultra-high purity surfactant for biologics and parenteral drug formulations
Ultra-high purity surfactant for biologics and parenteral drug formulations
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated